Palisade Bio, Inc.
News
Buy Rating on Palisade Bio Amidst UC Treatment Breakthrough and Strong Market Potential
TipRanks Financial Blog Palisade Bio (PALI - Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from Max...\n more…
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification
Globe Newswire Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90% of pediatric colitis patients Company is advancing lead program...\n more…
Palisade Bio (NASDAQ:PALI) Trading 3.2% Higher
Ticker Report Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report)'s share price shot up 3.2% on Wednesday . The stock traded as high as $3.56 and last traded at $3.55. 4,516 shares were traded during mid-day...\n more…
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire Carlsbad,CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ( Palisade , Palisade Bio , or the Company ), a biopharmaceutical company focused on developing and...\n more…
